THE FIVE DREADED WORDS
We didn't get it all
But it doesn't need to be this way
THE FIVE DREADED WORDS
We didn't get it all
But it doesn't need to be this way

CytoVeris is developing AI-powered cancer imaging technology that can deliver real-time cancer tissue visualization, enabling more precise intraoperative decisions and improving patient outcomes

The Data Tells us we Need to Improve the Precision of Cancer Resection

Breast Conservation Surgeries (BCS)

Up
to

35%

15-35% of BCS lumpectomies require a second surgery which often presents increased risk of complications ²

Transurethral Resection of Bladder Tumor (TURBT)

50%

of TURBT resections are incomplete, contributing to a higher risk of residual disease, early recurrence, and increased mortality¹

Radical Prostatectomies (RP)

25%

of RP procedures result in positive surgical margins, leading to a 2 to 3 fold increased in risk of biochemical recurrence³

1. Quality of diagnostic staging in patients with bladder cancer: A process‐outcomes link. K Chamie, et al. 3, 2015, Cancer, Vol. 121
2. A randomized, controlled trial of Cavity Shave margins in breast cancer. Chagpar, A. B et al. (2015). New England Journal of Medicine, 373(6)
3. Frequency of Positive Surgical Margin at Prostatectomy and Its Effect on Patient Outcome. K. Iczkowski, M. Scott. Prostate Cancer, Vol. 2011

  1. Quality of diagnostic staging in patients with bladder cancer: A process‐outcomes link. K Chamie, et al. 3, 2015, Cancer, Vol. 121
  2. A randomized, controlled trial of Cavity Shave margins in breast cancer. Chagpar, A. B et al. (2015). New England Journal of Medicine, 373(6)
  3. Frequency of Positive Surgical Margin at Prostatectomy and Its Effect on Patient Outcome. K. Iczkowski, M. Scott. Prostate Cancer, Vol. 2011

A 60% reduction in the breast cancer positive margin rate nationwide could avoid reoperations for 30,000 women annually.

Real-time imaging during prostatectomy could improve the odds of preservation of function and reduce recurrence for 90,000 men in the U.S. per year.

Real-time bladder resection imaging could avoid 70,000 repeat TURBT procedures per year in the U.S.

A 60% reduction in the breast cancer positive margin rate nationwide could avoid reoperations for 30,000 women annually.

Enabling SMARTER, more EFFICIENT, and more EFFECTIVE surgical visualization
The Tumor Margin Assessment and Profiling System,  TumorMAP™ is a multispectral imaging (MSI), Ultra high-definition (UHD), real-time intraoperative cancer imaging solution. TumorMAP produces an ultra-violet-excited autofluorescence image that enables surgeons to visually assess tissue that is indicative of cancer, based on changes in metabolism and tissue microstructure between healthy and unhealthy tissues.

All without the use of an imaging agent

Enabling SMARTER, more EFFICIENT, and more EFFECTIVE surgical visualization

The Tumor Margin Assessment and Profiling System,  TumorMAP™ is a multispectral imaging (MSI), Ultra high-definition (UHD), real-time intraoperative cancer imaging solution. TumorMAP produces an ultra-violet-excited autofluorescence image that enables surgeons to visually assess tissue that is indicative of cancer, based on changes in metabolism and tissue microstructure between healthy and unhealthy tissues.

All without the use of an imaging agent

AI POWERED - INTUITIVE OUTPUT

No DYE

REAL-TIME

INCREASED PRECISION

intraoperative tissue insights increase margin accuracy

SEAMLESS FIT  w/WORKFLOW

intra-operative efficiency require fewer resources

COST SAVINGS

of secondary operations & additional treatments

better outcomes

fewer complications, re-operations, radiation therapy, better functional outcomes

CytoVeris is aligned with the OR of the future

REAL-TIME

Easy to interpret tools to visualize cancer tissue in real-time during surgery and enable faster decisions

DATA


The future of surgery is DIGITAL – real-time information to surgeons to enhance intraoperative decision-making

PERSONALIZED

Accurate margin data allows customization of the surgical procedure to each patient’s needs

ROBOTICS

Platform technology presents ability to integrate TumorMAP™ imaging into robotics surgical procedures

CytoVeris' Platform Technology, TumorMAP™ powered by OncoSIGHT AI relies on the intersection of the natural biochemical characteristics of tissue, multispectral imaging and AI, and is under development to make a difference for patients across multiple disease areas.

OncoSIGHT AI™ is a proprietary, next generation tissue characterization algorithm that provides a safer, smarter and more reliable visualization of tissue indicative of cancer. cancerous tissue.

>> CLICK HERE  TO LEARN MORE ABOUT ONCOSIGHT AI

Indication

Pre-clinical research

OncoSIGHT AI training
OncoSIGHT AI validation

Feasibility Study

Pivotal Study

FDA Approval

breast
bladder
PROSTATE

CytoVeris is proving what’s possible during cancer surgery.

Be the first to know

Find Us

Contact Us

Media inquiries, please contact
[email protected]

Copyright © 2022 CytoVeris Inc. All rights reserved.

Scroll to Top

“CYTOVERIS NAMED "MURPHY'S INNOVATOR OF THE MONTH"

CytoVeris is a medical device company developing optical smart cancer imaging technologies designed to improve the clinical outcomes of patients undergoing certain cancer removal procedures by using enhanced clinical decision-making during surgery.